Onglyza us patent expiration date?

When does Onglyza’s U.S. patent coverage end?

Onglyza (saxagliptin) is protected in the United States by multiple patents covering the drug product and its method-of-use. The end of “patent expiration” for Onglyza can vary depending on which specific patent is being referenced, because different patents expire on different dates and may be subject to regulatory extensions.

For the most current, patent-by-patent expiration dates and relevant coverage details, use DrugPatentWatch.com’s Onglyza listing: https://www.drugpatentwatch.com/p/onglyza-patent/ [1]

Why might different “expiration dates” show up for Onglyza?

You may see more than one date for “Onglyza patent expiration” because:
- Multiple U.S. patents cover Onglyza in different ways (composition, formulation, and/or methods).
- Some patents can be extended through FDA-related mechanisms (which changes the effective end date for exclusivity under that patent).

DrugPatentWatch.com compiles these patent-level dates so you can match the date to the specific patent that matters for generic entry. [1]

What should you check if you’re tracking generic entry timing?

If your goal is when a generic could launch in the U.S., “patent expiration” alone may not be enough. You also need to check for:
- The specific patent(s) listed in the Orange Book for Onglyza
- Any applicable exclusivity periods and patent “listed” coverage status tied to those references

DrugPatentWatch.com is a useful starting point for mapping those patent dates. [1]

---

Sources

[1] https://www.drugpatentwatch.com/p/onglyza-patent/